GlassScriptPhysician profile
Zujun Li
NPI 1689662132
$55,111.65
in general payments reported to CMS, 2019-2025
18 companies · $9,154 in 2025
The $9,154 reported for 2025 was more than what 80% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,540 · 2020: $7,463 · 2021: $2,600 · 2022: $19K · 2023: $3,893 · 2024: $8,561 · 2025: $9,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Consulting Fee: $1,713 · Travel and Lodging: $1,427 · Food and Beverage: $785 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,662.50 |
| Consulting Fee | $1,712.50 |
| Travel and Lodging | $1,426.75 |
| Food and Beverage | $784.65 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $34,737.93 | 2022-2025 | Loqtorzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,552.98 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $5,335.67 | 2020-2023 | Imfinzi |
| Incyte Corporation | $3,571.22 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $2,100.00 | 2021 | |
| Emd Serono, INC. | $500.00 | 2021 | |
| Davol INC. | $163.42 | 2023 | Arista Ah Flexitip |
| Kerecis Limited | $67.68 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Axogen | $39.06 | 2024 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Ha+ Nerve Protector |
| Daiichi Sankyo INC. | $22.69 | 2024 | Enhertu |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zujun Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.